These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2057986)

  • 1. Neurological ischemic attack and interleukin-2 therapy.
    Donnet A; Tubiana N; Chinot O; Juin P
    Stroke; 1991 Jun; 22(6):819-20. PubMed ID: 2057986
    [No Abstract]   [Full Text] [Related]  

  • 2. Interleukin-2.
    Med Lett Drugs Ther; 1990 Sep; 32(826):85-6. PubMed ID: 2202892
    [No Abstract]   [Full Text] [Related]  

  • 3. Aldesleukin for metastatic renal cell carcinoma?
    Drug Ther Bull; 1993 Apr; 31(8):29-30. PubMed ID: 8348884
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study.
    Huland E; Burger A; Fleischer J; Fornara P; Hatzmann E; Heidenreich A; Heinzer H; Heynemann H; Hoffmann L; Hofmann R; Huland H; Kämpfer I; Kindler M; Kirchner H; Mehlhorn G; Moniak TH; Rebmann U; Roigas J; Schneider TH; Schnorr D; Schmitz HJ; Wenisch R; Varga Z; Vinke J
    Folia Biol (Praha); 2003; 49(5):183-90. PubMed ID: 14680292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angioneurotic oedema and urticaria during therapy with interleukin-2 (IL-2).
    Baars JW; Wagstaff J; Hack CE; Wolbink GJ; Eerenberg-Belmer AJ; Pinedo HM
    Ann Oncol; 1992 Mar; 3(3):243-4. PubMed ID: 1586626
    [No Abstract]   [Full Text] [Related]  

  • 6. [Bacteremia caused by Streptococcus equisimilis in a neoplastic patient treated with recombinant interleukin 2].
    Pedro-Botet ML; Ribelles Entrena N; Carrasco Miserachs I; Carles Galcerán J; Sabria-Leal M; Arnal J
    Enferm Infecc Microbiol Clin; 1990 Dec; 8(10):659-60. PubMed ID: 2098130
    [No Abstract]   [Full Text] [Related]  

  • 7. Atypical contrast reactions associated with systemic interleukin-2 therapy.
    Fishman JE; Aberle DR; Moldawer NP; Belldegrun A; Figlin RA
    AJR Am J Roentgenol; 1991 Apr; 156(4):833-4. PubMed ID: 2003450
    [No Abstract]   [Full Text] [Related]  

  • 8. [Gastric metastasis of cancer of the kidney].
    Mayeur D; David B; Boidart F; Dubrujeaud J
    Gastroenterol Clin Biol; 1993; 17(4):309-10. PubMed ID: 8339899
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma.
    Huland E; Heinzer H; Huland H
    Folia Biol (Praha); 2000; 46(6):241-50. PubMed ID: 11140857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
    Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective effect of norepinephrine infusion in acute renal insufficiency induced by interleukin 2 therapy.
    Allaouchiche B; Mercatello A; Tognet E; Négrier S; Moskovtchenko JF; Franks CR; Philip T
    Nephron; 1990; 55(4):438-9. PubMed ID: 2392201
    [No Abstract]   [Full Text] [Related]  

  • 12. Transient massive peripheral blood blastosis in patient with renal clear-cell carcinoma after treatment with high-dose recombinant interleuklin-2.
    del Mar Osma M; Gonzalez-Billalabeitia E; Ortuño FJ; Jerez A; Ayala F; Vicente V
    Lancet Oncol; 2007 Mar; 8(3):275-6. PubMed ID: 17329199
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously.
    Whitehead RP; Friedman KD; Clark DA; Pagani K; Rapp L
    Clin Cancer Res; 1995 Oct; 1(10):1145-52. PubMed ID: 9815906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA; Benyunes MC; Bianco JA; Fefer A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract]   [Full Text] [Related]  

  • 15. The promise of recombinant interleukin-2.
    Moldawer N; Carr E
    Am J Nurs; 2000 May; 100(5):35-9; quiz 40. PubMed ID: 10823166
    [No Abstract]   [Full Text] [Related]  

  • 16. Interleukin-2 in outpatients with renal cell carcinoma: SCAPP1 trial.
    Tourani JM; Grise P; Lucas V; Mayeur D; Dufour B; Di Palma M; Boaziz C; Pavlovitch JM; Pujade-Lauraine E; Larregain D; Untereiner M
    Cancer Biother Radiopharm; 1996 Oct; 11(5):297-300. PubMed ID: 10851507
    [No Abstract]   [Full Text] [Related]  

  • 17. Syndrome of inappropriate antidiuretic hormone secretion caused by high-dose bolus interleukin-2 therapy for metastatic melanoma.
    Green MR; Woolery JE; Elquza E
    Am J Ther; 2011 Sep; 18(5):e159-61. PubMed ID: 20592664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.
    Jafri M; Douis H; Porfiri E
    Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):657-8. PubMed ID: 18644704
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunomodulating therapy with rIL-2 and interferon alpha-induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (a pilot study).
    Demir G; Ozguroglu M; Sayhan N; Molinas-Mandel N; Demirelli F; Buyukunal E; Tuzuner N; Serdengecti S; Berkarda B
    Anticancer Res; 1999; 19(4C):3517-20. PubMed ID: 10629645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
    Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
    Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.